Followers | 251 |
Posts | 50151 |
Boards Moderated | 47 |
Alias Born | 08/29/2007 |
Sunday, October 01, 2023 2:30:39 PM
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent PPBT News
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 04/25/2024 11:00:00 AM
- Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology • GlobeNewswire Inc. • 03/14/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 09:06:16 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/05/2024 09:00:29 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 12:58:58 PM
- Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 12:55:55 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/27/2024 12:10:20 PM
- Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/13/2024 12:10:08 PM
- Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial • GlobeNewswire Inc. • 02/13/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 12:40:11 PM
- Purple Biotech Reaches Recommended Phase 2 Dose for NT219 • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2024 09:15:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/20/2023 01:06:31 PM
- Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors • GlobeNewswire Inc. • 12/20/2023 01:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 12:00:09 PM
- Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial • GlobeNewswire Inc. • 12/14/2023 11:50:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/21/2023 12:00:15 PM
- Purple Biotech Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/21/2023 11:50:17 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/15/2023 05:15:25 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 11/14/2023 09:13:12 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 11/13/2023 09:11:16 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/02/2023 11:04:08 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM